1. ICH Harmonised Tripartite Guideline: Pharmaceutical Development Q8 (R2);International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use:Geneva, August 2009.
2. Case Studies in the Development of Drug Substance Control Strategies
3. The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
4. bWang, X. A.; Sun, L.Q.; Sit, S.Y.; Sin, N.; Scola, P. M.; Hewawasam, P.; Good, A. C.; Chen, Y.; Campbell, J. A.Preparation of peptides as hepatitis C virus inhibitors. PCT Int. Appl. WO 2003099274 A1, 2003.
5. cSavage, S. A.; Domagalski, N. R.; Mack, B.; Vemishetti, P.; Qiu, Y.; Fenster, M.; Hallow, D. M.; Ferreira, G.; Rogers, A.; Lou, S.; Hobson, L.Preparation of asunaprevir as hepatitis C virus inhibitors. PCT Int. Appl. WO 2015200305 A1, 2015.